MannKind CorpMNKD
MNKD
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
78% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 51
74% more call options, than puts
Call options by funds: $20.3M | Put options by funds: $11.7M
58% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 26
11% more capital invested
Capital invested by funds: $971M [Q3] → $1.08B (+$109M) [Q4]
5% more funds holding
Funds holding: 229 [Q3] → 240 (+11) [Q4]
4.71% more ownership
Funds ownership: 56.16% [Q3] → 60.87% (+4.71%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 4 (+0) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for MNKD.
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
Positive
Seeking Alpha
1 month ago
MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question
MannKind's stock has fluctuated due to Tyvaso DPI's Q4 underperformance and competitive pressures, but it remains a key revenue driver for future profitability and R&D funding. Tyvaso DPI's potential expansion into IPF and MannKind's in-house developments in NTM-LD and IPF present significant growth opportunities despite competitive threats. MannKind's financial health is solid, with strong liquidity and manageable debt, supporting ongoing R&D and potential market expansion.
Neutral
Seeking Alpha
1 month ago
MannKind Corporation (MNKD) Q4 2024 Earnings Call Transcript
MannKind Corporation (NASDAQ:MNKD ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Corporate Participants Michael Castagna - Chief Executive Officer Chris Prentiss - Chief Financial Officer Conference Call Participants Olivia Brayer - Cantor Fitzgerald Faisal Khurshid - Leerink Partners Anish Nikhanj - RBC Capital Markets Andreas Argyrides - Oppenheimer Brandon Folkes - Rodman & Renshaw Yun Song - Wedbush Securities Operator Good afternoon and welcome to the MannKind Corporation Fourth Quarter and Year End 2024 Financial Results Earnings Call. As a reminder, this call is being recorded on February 26, 2025 and will be available for playback on the MannKind Corporation website shortly after the conclusion of this call and available for approximately 90 days.
Positive
Zacks Investment Research
1 month ago
Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Positive
Zacks Investment Research
1 month ago
MannKind (MNKD) Q4 Earnings Meet Estimates
MannKind (MNKD) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.02 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2024 revenues of $286M, +43% v. 2023; 4Q 2024 revenues of $77M, +31% v.
Neutral
Zacks Investment Research
1 month ago
Unveiling MannKind (MNKD) Q4 Outlook: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of MannKind (MNKD) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Neutral
GlobeNewsWire
1 month ago
MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
Neutral
Seeking Alpha
1 month ago
MoneyShow's Best Investment Ideas For 2025: Part 8
MoneyShow presents top investment ideas for 2025 from their contributors. This year's edition presents a broad mix of theme-based stock picks, momentum-driven high-flyers and beaten-up stocks with turnaround potential, along with some speculative plays and ETFs. Part 8 includes American Superconductor, Skye Bioscience, Healwell AI, Dell Technologies, MicroStrategy and MannKind, among others.
Neutral
GlobeNewsWire
2 months ago
MannKind Expands Executive Leadership Team
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focusing on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Dominic Marasco, RPh, has joined the company as President, Endocrine Business Unit, effective January 6, 2025.
Charts implemented using Lightweight Charts™